Definition and Prevalence
Sleeping problems (insomnia and poor quality sleep) are common in people requiring palliative care, and often have a significant impact on quality of life. [3-6] They are particularly common in patients with COPD,  patients with heart disease,  end-stage renal disease,  end-stage liver disease,  and cancers associated with the lung  and the central nervous system.  The problems may be a combination of difficulty going to sleep, fragmented sleep, or early morning waking. Patients may complain that their sleep is not refreshing and sleep disturbances can exacerbate other symptoms such as pain. 
Insomnia can also be a problem for the patient’s caregivers and contributes to the burden of caregiving.  The sleeping problems of caregivers may continue into bereavement – either as a transient part of normal grief and bereavement, or a significant problem if the bereavement is complex or associated with depression.
Many life-limiting conditions or the treatments associated with these conditions cause sleep problems. There are a number of potentially modifiable problems which may contribute to sleeplessness: 
- Depression, anxiety
- Obstructive sleep apnoea, or other primary sleep disorder
- Dyspnoea, cough, pleural effusion
- Nausea, vomiting
- Movement disorders eg, restless legs, akathisia
- Night sweats
- Pruritis (itch)
- Environmental disruption, especially for in-patients
- Changed activity patterns
- Altered circadian rhythm
- Reduced bed mobility, and physical problems that limit comfortable sleeping position
- Medications eg, steroids
- Incontinence or nocturia.
There are a number of screening and assessment tools for sleep disturbances. One of the most common, validated tools used in the general population is the Pittsburgh Sleep Quality Index (PSQI).  The Edmonton Symptom Assessment System (ESAS) was recently studied for its suitability to screen for sleeping problems in patients with advanced cancer.  The authors found the ESAS was appropriate to use and recommended routine screening for patients in a palliative care setting.
A number of systematic reviews have examined both pharmacological and non-pharmacological interventions for sleep disturbances. A meta-analysis  was unable to identify sufficient evidence to draw conclusions about the use of benzodiazepines in palliative care. Agents that were included in the meta-analysis were all benzodiazepines, as well as zolpidem, zopiclone and zalpelon. Midazolam is the most commonly used benzodiazepam in palliative care, although it is rarely used specifically for sleeping problems and there is no evidence to support its use for sleep.  Melatonin has been used in a number of populations to assist with sleep. [15,16] It has been studied in advanced cancer with limited efficacy. 
Non-pharmacological interventions, such as exercise, sleep hygiene, mind-body practices and changes to the environment have been examined for efficacy at improving sleep. [3,17,18] There is low quality evidence to support these interventions. A systematic review of complimentary therapies in palliative care found no supporting evidence for these interventions to manage sleeping problems. 
- Based on the available evidence, it is suggested that the clinical assessment of insomnia should focus on:
- reversible factors which may contribute to sleeping problems
- prognosis, which determines the length of time for which night sedation is likely to be needed, in order to minimise the use of long-term (greater than 8 weeks) sedative hypnotics.
- The Edmonton Symptom Assessment System (ESAS) can be recommended for use in palliative care. 
- If the patient has a prognosis of several months, non-pharmacological options for treatment should also be considered. 
- Non-pharmacological interventions have limited evidence in the palliative care population, but in primary insomnia it may be beneficial to review environmental issues and sleep hygiene (including avoidance of napping and sleeping in where possible), behaviour therapies, and relaxation techniques. 
- Medications which have sedating properties may contribute to night sedation (eg, tricyclic or other sedating antidepressants, antihistamines, or antipsychotics) but should be carefully assessed with regard to their side effect profile, and are likely to be best used where there is a specific indication. 
- There is evidence that chronic use of sedative hypnotics in palliative care patients results in increased side effects without long term efficacy. [1,2] Patterns of benzodiazepine use in palliative care patients, their effectiveness, and their adverse effects are being studied in phase 4 clinical trials.
- Melatonin has been identified as a medication with the potential to reduce sleep latency, and may be an avenue for future research. 
- There are few validated instruments for assessing and researching sleep problems in palliative care.